Anbio Biotechnology (NNNN) Other Non-Current Assets (2023)
Anbio Biotechnology (NNNN) posted quarterly Other Non-Current Assets of $1293.0 for Q4 2023.
Anbio Biotechnology (NNNN) Other Non-Current Assets (2023) Analysis & Trends
Anbio Biotechnology (NNNN) has reported Other Non-Current Assets for 1 consecutive years, with $1293.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Other Non-Current Assets changed N/A year-over-year to $1293.0; the TTM figure through Dec 2023 stood at $1293.0 (changed N/A YoY), while the FY2023 annual figure was $1293.0, changed N/A from the prior year.
- Other Non-Current Assets steadied at $1293.0 in Q4 2023 per NNNN's latest filing.
- Across five years, Other Non-Current Assets topped out at $1293.0 in Q4 2023 and bottomed at $1293.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | - |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 2.55 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 434.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 457.39 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 22.91 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 82.80 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 904.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 672.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 669.00 Mn |
| 10 | Anbio Biotechnology | 301.77 Mn | 289.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1,293.00 |